Peer-influenced content. Sources you trust. No registration required. This is HCN.
Conexiant
Breast cancer screening remains a persistent area of variation in clinical practice. Updated guidance from the American College of Physicians aims to clarify when screening offers meaningful benefit for average‑risk patients — and when it may not.
Internal Medicine April 22nd 2026
Annals of Internal Medicine
Supplemental MRI for women with extremely dense breasts and higher-than-average risk “could be cost-effective if MRI costs and false-positive biopsy rates are reduced.” — Tosteson et al., Annals of Internal Medicine
Oncology, Medical April 14th 2026
“Basically women were told: ‘You’re lucky to be alive. Some pain is expected. Suck it up and deal with it.'” — Dr. Sean Mackey, Stanford University Pain Medicine
Obstetrics & Gynecology April 8th 2026
Cancer Therapy Advisor
Disease recurrence in HR+/HER2– early BC (EBC) can occur over decades; however, the hazard of recurrence is highest during the first 2 years of adjuvant endocrine therapy, a period associated with endocrine resistance and early metastatic progression.
Oncology, Medical March 30th 2026
The primary end point was the area under the curve (AUC) of the daily worst bone pain score (assessed using the “worst pain” question from the Brief Pain Inventory, a 0 to 10 numerical rating scale [NRS]) for 5 consecutive days in the first chemotherapy cycle.
Hematology/Oncology March 30th 2026
Medical News Today (MNT)
“Given that studies project cases will increase by 38-54% and deaths by 68-71% by 2050, prevention through lifestyle modification becomes critically important.” – Amy Bremner, MD
Obstetrics & Gynecology March 11th 2026